How Much Does Revlimid Cost With Medicare?
Revlimid (Lenalidomide) costs an average of $12,786 per Medicare Part D claim, with total Medicare spending of $7825.0M in the latest year. No generic alternative is currently available.
Key Facts: Revlimid Cost
- Medicare Part D avg
- $12,786/claim
- Likely Part D tier
- Tier 4-5 (specialty)
- Annual cost/patient
- $134,914
- Generic available
- No
- Manufacturer
- Bristol-Myers Squibb
- Treats
- Cancer
- Patent expires
- 2027-03-15
- YoY price change
- -3.4%
Source: CMS Medicare Part D Spending Dashboard. Tier placement inferred from typical formulary norms — confirm with your specific Part D plan.
Revlimid Medicare Coverage & Out-of-Pocket Cost
Revlimid is covered under Medicare Part D, with the program paying an average of $12,786 per prescription fill. Revlimid typically falls on Tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000.
Your actual out-of-pocket cost depends on three factors: (1) formulary tier — your plan's specific placement; (2) deductible status — most plans require you to meet up to a $590 deductible (2025) before copays kick in; (3) coverage phase — initial coverage, then the donut hole was eliminated in 2025, replaced by a hard $2,000 annual out-of-pocket cap under the Inflation Reduction Act. Once you hit $2,000 in true out-of-pocket spending, the rest of your Part D drugs are free for the year.
No generic is currently available for Revlimid. Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute prohibits them for federal program enrollees), but charity foundations such as the PAN Foundation, NeedyMeds, and the HealthWell Foundation offer copay grants for many cancer drugs. The Medicare Extra Help (LIS) program also reduces Part D costs to near-zero for income-qualified beneficiaries (under 150% of the federal poverty level).
For cash-pay or commercial insurance scenarios, compare prices using GoodRx, SingleCare, or Cost Plus Drugs before filling — discount-program prices sometimes beat Part D copays for lower-cost generics.
Revlimid is manufactured by Bristol-Myers Squibb and prescribed primarily for Cancer. In the most recent Medicare Part D data, 612,000 claims were filed for 58,000 unique beneficiaries, at an average cost of $12,786 per claim. Average annual cost per beneficiary is $134,914.
Year over year, Medicare spending on Revlimid has decreased by -3.4%. No generic substitute is available, so the brand-name price reflects the full market cost. Its patent expires 2027-03-15.
Revlimid belongs to the Cancer Immunotherapy & Targeted Therapy class. Checkpoint inhibitors (Keytruda, Opdivo) unleash the immune system to attack cancer by blocking proteins (PD-1/PD-L1) that cancer cells use to hide. Kinase inhibitors (Ibrance, Xtandi) block specific enzymes that drive cancer cell growth. IMiDs (Revlimid) modify the immune system and directly kill cancer cells. CDK4/6 inhibitors (Ibrance, Kisqali) stop cancer cells from dividing.
Key Data
| Metric | Value |
|---|---|
| Avg Cost Per Claim | $12,786 |
| Total Medicare Spending | $7825.0M |
| Total Claims | 612,000 |
| Beneficiaries | 58,000 |
| Generic Available | No |
| Year-Over-Year Change | -3.4% |
Other Drugs for Cancer
Frequently Asked Questions
Medicare Part D pays an average of $12,786 per claim for Revlimid. Revlimid is typically placed on Tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000. As of 2025, total annual out-of-pocket on Part D is capped at $2,000 under the Inflation Reduction Act.
Yes. Revlimid appears in Medicare Part D claims data, with 58,000 beneficiaries filling 612,000 prescriptions in the latest year. Specific coverage depends on your plan's formulary — call the number on your insurance card or check the plan's Summary of Benefits to confirm prior authorization, step therapy, or quantity limit requirements.
Revlimid (Lenalidomide) costs an average of $12,786 per Medicare Part D claim, with total Medicare spending of $7825.0M in the latest year. No generic alternative is currently available.
No. As of the latest FDA Orange Book data, there is no generic version of Revlimid (Lenalidomide). Patent protection extends until 2027-03-15, after which generics may enter the market.
Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute), but several options exist: (1) Apply to charity copay foundations like the PAN Foundation, NeedyMeds, HealthWell Foundation, or Patient Advocate Foundation — many cover cancer drugs; (2) Ask your prescriber about therapeutic alternatives in the same drug class that may be on a lower tier; (3) For some drugs, paying cash via GoodRx or Cost Plus Drugs can beat your Medicare copay — always compare before filling; (4) If your income is below 150% of the federal poverty level, you may qualify for the Medicare Extra Help (Low-Income Subsidy) program, which reduces Part D costs to near-zero.
Revlimid is manufactured by Bristol-Myers Squibb. The FDA application number is NDA021880.
Revlimid (Lenalidomide) is primarily prescribed for Cancer.
Medicare Part D spending on Revlimid has decreased -3.4% year over year. Total program spending reached $7825.0M in the latest reporting year.
Revlimid (Lenalidomide) costs an average of $12,786 per Medicare Part D claim, with total Medicare spending of $7825.0M in the latest year. No generic alternative is currently available.
The data source behind this answer is CMS Medicare Part D Drug Spending data. Every figure on the page traces back to that source; the methodology page describes the inputs and the refresh cadence in full detail.
A practical caveat: the headline answer above reflects the most recent CMS Medicare Part D Drug Spending data vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.
Source: CMS Medicare Part D Spending, 2026.